The Osong Medical Industry Promotion Foundation (KBIOHealth, chaired by Myung-Soo Lee) signed a business cooperation agreement with GBIOLOGICS, Ltd. (CEO David Song) on Thursday, the 20th, at GBIOLOGICS’ headquarters in Pangyo. The agreement is titled “Partnership for the Development of Innovative Autoimmune Therapies for Global Market Expansion.”
This partnership aims to accelerate the commercialization of autoimmune disease treatments and establish a cooperative framework for entry into global markets.
Both institutions plan to strengthen a full-cycle collaboration model—from research and development of innovative biopharmaceuticals to commercialization and global expansion—while jointly enhancing the competitiveness of Korea’s biohealth industry.
Under the agreement, the two organizations will cooperate in the following areas:
- Joint R&D of autoimmune therapies based on recombinant gene technology
- Joint planning and response to government-led R&D projects
- Co-hosting academic conferences, seminars, and workshops
- Exchange of professional personnel
- Shared use of research facilities and infrastructure
Hye-Jeong Han, Director of KBIOHealth’s New Drug Development Support Center, stated:
“Through collaboration with GBIOLOGICS, which possesses innovative technological capabilities, we will accelerate the commercialization of autoimmune disease treatments.”
Chairman Myung-Soo Lee of KBIOHealth added:
“KBIOHealth will continue to strengthen connections with government, industry, and research institutions to enhance the international competitiveness of the advanced bio industry and establish a global new drug development ecosystem for K-Bio.”
CEO David Song of GBIOLOGICS remarked:
“Based on KBIOHealth’s research infrastructure and network, we will enhance our global-level clinical and commercialization capabilities. This collaboration will speed up the development of innovative autoimmune therapies and expand K-Bio’s presence in the global market.”
G-Biologics recently demonstrated its technological strength by winning the “Seoul-BMS Innovation Square Challenge” against a 30-to-1 competition ratio.
Moving forward, the two institutions will continue to pursue concrete cooperative projects such as joint responses to government R&D initiatives and co-hosted seminars, aiming to develop this partnership into a model case for K-Bio’s global expansion.
Meanwhile, since its establishment in 2010, KBIOHealth has provided integrated support across all areas of biohealth—including new drug development, medical devices, non-clinical trials, pharmaceutical production, and regulatory science. Celebrating its 15th anniversary this year, KBIOHealth is striving to become a leading research and industrial hub in the “Bio 4.0” era.
Jungdo Ilbo / Reporter Jae-Cheon Eom
